ZBTB7C, downregulated in CRC, is thought to block Myc and tumor cell glutaminolysis, thus increasing immune cell proliferation due to the glutamine surplus in the tumor microenvironment and attenuating CRC cell proliferation [98]. Here, ZBTB7C is linked to neoplasm.